Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
January 10, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesInjectable compositions, nanoparticles useful therein, and process of manufacturing same Chemical compounds Triiodoisophthalamide X-ray contrast agent Process for the preparation of activated pharmaceutical compositions Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof Microdroplets of water-insoluble drugs and injectable formulations containing same Method for making uniformly sized particles from water-insoluble organic compounds 5118528 Surface modified drug nanoparticles Iodinated aroyloxy carboxamides InventorsApplicationNo. 370998 filed on 01/10/1995US Classes:424/9.45, Halogenated benzene ring containing424/1.29, Coated, impregnated, or colloidal particulate (e.g., microcapsule, micro-sphere, micro-aggregate, macro-aggregate)424/9.4, X-ray contrast imaging agent (e.g., computed tomography, angiography, etc.)424/488, Polysaccharides (e.g., cellulose, etc.)424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)424/490Coated (e.g., microcapsules)ExaminersPrimary: Hollinden, Gary E.Assistant: Hartley, Michael G. Attorney, Agent or FirmInternational ClassesA61K 049/04A61K 009/14 AbstractThis invention describes the coprecipitation of nanoparticulate pharmaceutical agent dispersion via a process that comprises the dissolution of the said pharmaceutical agent in combination with a crystal growth modifier (CGM) in an alkaline solution and then neutralizing the said solution with an acid in the presence of suitable surface-modifying surface-active agent or agents to form a fine particle dispersion of the said pharmaceutical agent, followed by steps of diafiltration clean-up of the dispersion and then concentration of it to a desired level. This process of dispersion preparation leads to microcrystalline particles of Z-average diameters smaller than 400 nm as measured by photon correlation spectroscopy. Various modification of precipitation schemes are described, many of which are suitable for large-scale manufacture of these agent dispersions. It has been discovered that coprecipitation with CGM leads to smaller particle size compared to a case where precipitation is carried out using the pharmaceutical agent alone. Thus, this dispersion of instant invention is expected to have greater bioavailability. The CGM compound is a compound that has at least about 75% of its chemical structure identical to that of the pharmaceutical agent.Other References
Field of SearchX-ray contrast imaging agent (e.g., computed tomography, angiography, etc.)Halogenated benzene ring containing Liposomes Ultrasound contrast agent Polysaccharides (e.g., cellulose, etc.) Particulate form (e.g., powders, granules, beads, microcapsules, and pellets) Coated (e.g., microcapsules) | |
